论文部分内容阅读
用人涎腺粘液表皮样癌ＭＥＣ—１细胞在体内外研究了５—氟脲嘧啶（５—ＦＵ）与分化诱导剂六亚甲基双乙酰胺（ＨＭＢＡ）的联合抗癌作用。体外ＭＴＴ法检测结果表明短时间、低剂量应用５—ＦＵ，随后应用ＨＭＢＡ可显著加强５—ＦＵ对ＭＥＣ—１细胞的毒性作用，同时５—ＦＵ亦加强ＨＭＢＡ对ＭＥＣ—１细胞的生长抑制作用，二者表现为协同作用。裸鼠体内抑癌实验亦证实了体外实验结果，联合用药的抑瘤率、生命延长率均高于单独用药组。结果提示ＨＭＢＡ联合５—ＦＵ对粘液表皮样癌的临床治疗可能具有一定应用价值。
The combined anticancer effect of 5-fluorouracil (5-FU) and hexamethylene bisacetamide (HMBA), a differentiation-inducing agent, was investigated in vivo using human salivary mucoepidermoid carcinoma MEC-1 cells. The results of in vitro MTT assay showed that short-term, low-dose application of 5-FU, followed by the application of HMBA can significantly enhance the 5-FU effect on the MEC-1 cell toxicity, while 5-FU also enhance the HMBA inhibition of MEC-1 cell growth Both show a synergistic effect. Tumor suppressor experiments in nude mice also confirmed the results of in vitro experiments. The antitumor rate and prolongation of life of combined drugs were higher than those of the drug alone group. The results suggest that HMBA combined with 5-FU may have a certain value in the clinical treatment of mucoepidermoid carcinoma.